As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

"With its potential for screening, recurrence monitoring, treatment guidance, and prognosis prediction, utDNA is poised to transform bladder cancer management and personalize patient care." — Liang ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

Explore new findings on bladder cancer and inflammation's role in immune suppression. Discover insights to improve treatment.

A non-invasive, high-accuracy surveillance test for bladder cancer has the potential to improve patient experience, streamline workflows, and reduce overall cost of care” — Megann Vaughn Watters, Vice ...

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well ...

India, March 17 -- Latest study shows a serious link between emergency room wait times and patient survival. One in ten accident and emergency patients (A&E patients) with visible blood in urine ...

Their makers claim they can detect dozens of cancer types — but some scientists say they could be missing many cancers or ...

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?